hVIVO (LSE:HVO) is relying on a heavily weighted second half after reporting a sharp fall in revenue and a swing to loss in the first six months of 2026. In interim results published on 15 September 2026, the human challenge trial specialist said revenue fell to £16.3m from £24.2m, while its contracted order book more than doubled to £65m. Management expects revenue to roughly double between the first and second halves of the year, guiding to full-year revenue of about £47m.
What the Company Does
hVIVO is a contract research organisation best known for human challenge trials, in which healthy volunteers are deliberately exposed to a pathogen in a controlled setting to test vaccines and antivirals. It runs quarantine facilities in London and has broadened its offering into early-phase clinical trials, laboratory services and consulting. During the first half it launched a unified hVIVO brand across four service lines: consulting, clinical trials, human challenge trials and laboratories.
Latest Developments
The interim period brought three new human challenge trial contracts, including a pivotal Phase III whooping cough vaccine trial with ILiAD Biotechnologies, plus two influenza studies. Proposal volumes rose about 45% year on year, and the company said repeat customers accounted for roughly three-quarters of group revenue. Chief executive Yamin 'Mo' Khan pointed to "a clear improvement in commercial momentum".
In August 2026 the group acquired CRS Berlin, which adds Phase I and II capability in dermatology and women's health. Initial consideration was a nominal €25,000, with further payments of 18% of annual revenue for three years subject to a minimum revenue threshold. Including CRS Berlin's own order book of about €10m, hVIVO put its pro forma order book at a record £72m.
There is also a change in the finance function. Chief financial officer Stephen Pinkerton was due to retire on 30 September 2026, with non-executive director Richard Cotton stepping in as interim CFO.
Financial Picture
The first-half figures showed the impact of lower activity. EBITDA before exceptional items was a loss of £4.5m, against a £3.0m profit a year earlier, and the loss for the period widened to £6.5m from £0.2m. Basic loss per share was 0.94p. Operating cash flow was slightly positive at £0.3m thanks to working capital inflows, and cash stood at £13.0m at 30 June 2026, compared with £14.3m at the end of 2025. No interim dividend was declared.
The full-year guidance of about £47m reflects project deferrals into 2027 and 2028 and includes around £3m from CRS Berlin. The company expects positive adjusted EBITDA in the second half and a low single-digit adjusted EBITDA loss for 2026 as a whole.
Sector and Index Context
hVIVO is one of the more established healthcare services names on the FTSE AIM All Share Index. The wider contract research sector has faced uneven biotech funding and delayed study starts, which helps explain why hVIVO's revenue has proved lumpy despite a growing pipeline of proposals.
Key Risks
The investment case now hinges on execution of a back-weighted year. Further trial deferrals, as seen in the first half, could push revenue out again and put pressure on guidance. Human challenge trials are large, discrete contracts, so the timing of a small number of studies can swing results materially. Integrating CRS Berlin and managing a finance leadership transition add further moving parts.
What to Watch Next
Investors will be watching for a year-end trading update confirming whether the near doubling of second-half revenue has been delivered, and whether the order book continues to convert. Management has said it expects a return to significant growth in 2027, making any early commentary on next year's outlook, and the appointment of a permanent CFO, important markers.






Please wait processing your request...